{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:46:06Z","timestamp":1791751566656,"version":"4.3.4"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Government Ministry of Health","doi-asserted-by":"publisher","award":["PNRR-TR1-2023-12378400"],"award-info":[{"award-number":["PNRR-TR1-2023-12378400"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.09.016","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:47Z","timestamp":1791511007000},"page":"43-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular biomarkers in uterine sarcomas: a review of reviews with genomic data integration"],"prefix":"10.1016","volume":"214","author":[{"given":"V.","family":"Iacobelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dababou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Gubitosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mastrogiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sabetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Trozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Duranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciccarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Riziero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Monterossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Garganese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S2","key":"10.1016\/j.ygyno.2026.09.016_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ijgo.12613","article-title":"Uterine sarcomas","volume":"143","author":"Mbatani","year":"2018","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.016_bb0010","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1055\/a-1545-4279","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"H\u00f6hn","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.016_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2022.07.031","article-title":"Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group","volume":"167","author":"Croce","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.016_bb0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.09.016_bb0025","article-title":"Molecular landscape of endometrial stromal tumors","volume":"9","author":"Brunetti","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0030","article-title":"BCOR abnormalities in endometrial stromal sarcoma","volume":"57","author":"Fayoumi","year":"2025","journal-title":"Gynecol. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0035","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/cas.13613","article-title":"Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma","volume":"109","author":"Tsuyoshi","year":"2018","journal-title":"Cancer Sci."},{"issue":"15","key":"10.1016\/j.ygyno.2026.09.016_bb0040","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1158\/1078-0432.CCR-14-3141","article-title":"Clinically relevant molecular subtypes in leiomyosarcoma","volume":"21","author":"Guo","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.ygyno.2026.09.016_bb0045","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061561","article-title":"Interrogating the genomic landscape of uterine leiomyosarcoma: a potential for patient benefit","volume":"14","author":"Dall","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13643-019-1252-9","article-title":"Preferred Reporting Items for Overviews of Reviews (PRIOR): a protocol for development of a reporting guideline for overviews of reviews of healthcare interventions","volume":"8","author":"Pollock","year":"2019","journal-title":"Syst. Rev."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0065","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0070","article-title":"Uterine mesenchymal tumors: updates on pathology, molecular landscape, and therapeutics","volume":"60","author":"Alodaini","year":"2024","journal-title":"Medicina (Mex.)"},{"key":"10.1016\/j.ygyno.2026.09.016_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2023.02.009","article-title":"Endometrial stromal tumors of the uterus: epidemiology, pathological and biological features, treatment options and clinical outcomes","volume":"171","author":"Gadducci","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.016_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092420","article-title":"The role of MicroRNAs in uterine leiomyosarcoma diagnosis and treatment","volume":"15","author":"Psilopatis","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ygyno.2026.09.016_bb0205","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/14737159.2017.1311790","article-title":"Molecular characteristics of uterine sarcomas","volume":"17","author":"Davidson","year":"2017","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.016_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102567","article-title":"Epigenetic features in uterine leiomyosarcoma and endometrial stromal sarcomas: an overview of the literature","volume":"10","author":"De Almeida","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ygyno.2026.09.016_bb0215","article-title":"High-grade endometrial stromal sarcoma: molecular alterations and potential immunotherapeutic strategies","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1066896920958120","article-title":"Gynecological sarcomas: molecular characteristics, behavior, and histology-driven therapy","volume":"29","author":"Libertini","year":"2021","journal-title":"Int. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.013","article-title":"Genetic aberrations in soft tissue leiomyosarcoma","volume":"275","author":"Yang","year":"2009","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.016_bb0230","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/path.5617","article-title":"Genetic drivers and cells of origin in sarcomagenesis","volume":"254","author":"Kannan","year":"2021","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.016_bb0235","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5858\/arpa.2016-0284-SA","article-title":"Recent developments in surgical pathology of the uterine corpus","volume":"141","author":"Hanley","year":"2017","journal-title":"Arch. Pathol. Lab Med."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/gcc.22910","article-title":"NTRK and other recently described kinase fusion positive uterine sarcomas: a review of a group of rare neoplasms","volume":"60","author":"Croce","year":"2021","journal-title":"Genes Chromosom. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.016_bb0245","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/CCO.0000000000000462","article-title":"Gynecological sarcomas: what\u2019s new in 2018, a brief review of published literature","volume":"30","author":"Gantzer","year":"2018","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0250","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0255","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.mpdhp.2017.05.007","article-title":"New developments in endometrial stromal sarcoma","volume":"23","author":"Vroobel","year":"2017","journal-title":"Diagn. Histopathol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0260","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2011.07.003","article-title":"Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential","volume":"25","author":"Ip","year":"2011","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0265","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00428-018-2470-6","article-title":"Recent advances in the histological and molecular classification of endometrial stromal neoplasms","volume":"473","author":"Ferreira","year":"2018","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0270","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejogrb.2023.06.016","article-title":"Uterine sarcomas: a critical review of the literature","volume":"287","author":"Giannini","year":"2023","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0275","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5858\/arpa.2023-0324-RA","article-title":"The spectrum of fusions occurring in non\u2013smooth muscle mesenchymal uterine tumors: a review of the current knowledge","volume":"149","author":"Dundr","year":"2025","journal-title":"Arch. Pathol. Lab Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0285","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/jclinpath-2015-202945","article-title":"Perivascular epithelioid tumours (PEComas) of the gynaecological tract","volume":"68","author":"Conlon","year":"2015","journal-title":"J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.09.016_bb0290","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.mpdhp.2021.09.005","article-title":"An update in pathologic diagnosis of uterine mesenchymal tumours","volume":"27","author":"Chapel","year":"2021","journal-title":"Diagn. Histopathol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0295","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/jog.14436","article-title":"Endometrial stromal sarcoma: a review of rare mesenchymal uterine neoplasm","volume":"46","author":"Capozzi","year":"2020","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0300","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2020.08.016","article-title":"Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa\u2019 italiana di Ginecologia E Ostetricia)","volume":"139","author":"Ferrandina","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.016_bb0305","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-0864-5","article-title":"Circulating transcripts and biomarkers in uterine tumors: is there a predictive role?","volume":"22","author":"De Bruyn","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0310","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/his.14008","article-title":"Uterine mesenchymal tumours: recent advances","volume":"76","author":"Momeni-Boroujeni","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2026.09.016_bb0315","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1097\/IGC.0000000000000239","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract","volume":"24","author":"Friedlander","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0320","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000494067","article-title":"Uterine adenosarcoma","volume":"41","author":"Ulrich","year":"2018","journal-title":"Oncol. Res. Treat."},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11912-016-0552-7","article-title":"Uterine adenosarcoma: a review","volume":"18","author":"Nathenson","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2024.10.008","article-title":"Hormonal therapy in low-grade endometrial stromal sarcoma; what is the current standard of care?","volume":"191","author":"Saab","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.016_bb0085","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/ijgc-2023-005229","article-title":"An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent\/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)","volume":"34","author":"Trozzi","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.016_bb0330","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tjog.2016.04.034","article-title":"Uterine sarcoma part II\u2014uterine endometrial stromal sarcoma: the TAG systematic review","volume":"55","author":"Horng","year":"2016","journal-title":"Taiwan. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.016_bb0130","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2\u2013p53 antagonist Brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0335","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41571-018-0012-4","article-title":"Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours","volume":"15","author":"Dufresne","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.016_bb0140","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMoa2508820","article-title":"Phase 1 study of rezatapopt, a p53 reactivator, in TP53 Y220C\u2013mutated tumors","volume":"394","author":"Dumbrava","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0340","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel therapeutics in the treatment of uterine sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0345","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.016_bb0350","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN guidelines\u00ae insights: uterine neoplasms, version 3.2025: featured updates to the NCCN guidelines\u00ae","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.ygyno.2026.09.016_bb0355","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(09)70226-8","article-title":"Clinical management of uterine sarcomas","volume":"10","author":"Amant","year":"2009","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0360","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41388-022-02582-6","article-title":"ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study","volume":"42","author":"Lemech","year":"2023","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.ygyno.2026.09.016_bb0370","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.ygyno.2026.09.016_bb0375","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-22-2092","article-title":"A single-arm phase Ib\/II study of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2026.09.016_bb0380","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2026.09.016_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/cells13131106","article-title":"Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy","volume":"13","author":"Yang","year":"2024","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.016_bb0390","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/s41416-023-02416-6","article-title":"Axitinib in patients with advanced\/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata","volume":"129","author":"Woll","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2026.09.016_bb0395","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2025.3608","article-title":"Guidelines for next-generation sequencing in sarcoma diagnosis and treatment: a consensus review","volume":"11","author":"Serrano","year":"2025","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0400","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0405","series-title":"Journal of Clinical Oncology","article-title":"A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304)","year":"2026"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2026.09.016_bb0185","doi-asserted-by":"crossref","first-page":"11506","DOI":"10.1200\/JCO.2021.39.15_suppl.11506","article-title":"NCI protocol 10250: a phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma","volume":"39","author":"Ingham","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0410","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0959-8049(02)80608-6","article-title":"Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"38","author":"Van Oosterom","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2006.01.024","article-title":"A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate","volume":"101","author":"Salvatierra","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0415","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-008-0786-7","article-title":"Detection of complete response to imatinib mesylate (Glivec\u00ae\/Gleevec\u00ae) with 18F-FDG PET\/CT for low-grade endometrial stromal sarcoma","volume":"63","author":"Kalender","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0420","article-title":"COL1A1::PDGFB fusion-associated uterine sarcoma and response to Imatinib: a case report","volume":"49","author":"Chapagain","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0425","article-title":"COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy","volume":"34","author":"Grindstaff","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.016_bb0430","article-title":"COL1A1::PDGFB fusion-associated uterine fibrosarcoma: a case report and review of the literature","volume":"7","author":"Rota","year":"2024","journal-title":"Cancer Rep."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0435","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0440","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/annonc\/mdp431","article-title":"Successful PDGFR-\u03b1\/\u03b2 targeting with imatinib in uterine sarcoma","volume":"20","author":"Trojan","year":"2009","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.ygyno.2026.09.016_bb0445","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.ejca.2013.08.005","article-title":"Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature","volume":"49","author":"Van Kruchten","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.09.016_bb0450","article-title":"Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas","volume":"40","author":"Crowley","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0455","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ygyno.2021.09.010","article-title":"Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor\/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: the PARAGON trial (ANZGOG 0903)","volume":"163","author":"Edmondson","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0460","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2021.02.016","article-title":"Phase 2 study of anastrozole in patients with estrogen receptor\/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: the PARAGON trial (ANZGOG 0903)","volume":"161","author":"Friedlander","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0465","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature","volume":"101","author":"Pink","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0470","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/IGC.0b013e31825b7de8","article-title":"Uterine sarcoma and aromatase inhibitors","volume":"22","author":"Altman","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2 Part 2","key":"10.1016\/j.ygyno.2026.09.016_bb0475","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.AOG.0000267533.56546.c2","article-title":"Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor","volume":"110","author":"Hardman","year":"2007","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.09.016_bb0480","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0485","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.10.064","article-title":"Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors","volume":"116","author":"O\u2019Cearbhaill","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0490","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3329-4-5","article-title":"Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors","volume":"4","author":"Thanopoulou","year":"2014","journal-title":"Clin. Sarcoma Res."},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.016_bb0495","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1136\/ijgc-2020-001519","volume":"30","author":"Ray-Coquard","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0500","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/15384047.2016.1167290","article-title":"Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa","volume":"17","author":"Gao","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"17","key":"10.1016\/j.ygyno.2026.09.016_bb0505","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1158\/1078-0432.CCR-19-0288","article-title":"Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas)","volume":"25","author":"Sanfilippo","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"33","key":"10.1016\/j.ygyno.2026.09.016_bb0165","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"nab -sirolimus for patients with malignant perivascular epithelioid cell Tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0090","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.18632\/oncotarget.13270","article-title":"The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis","volume":"8","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.016_bb0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ygyno.2018.03.007","article-title":"Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway","volume":"149","author":"Przybyl","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.016_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/gcc.22907","article-title":"Molecular pathogenesis and prognostication of \u201clow-grade\u201d and \u201chigh-grade\u201d endometrial stromal sarcoma","volume":"60","author":"Micci","year":"2021","journal-title":"Genes Chromosom. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12885-018-3999-0","article-title":"A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report","volume":"18","author":"Verschoor","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2026.09.016_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41389-021-00327-w","article-title":"YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF\/MAPK and Hippo pathways","volume":"10","author":"Ou","year":"2021","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00432-019-03093-w","article-title":"DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics","volume":"146","author":"Kommoss","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.016_bb0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2020.02.024","article-title":"Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss","volume":"157","author":"Lin","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.016_bb0135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pharmthera.2019.06.010","article-title":"TP53 in bone and soft tissue sarcomas","volume":"202","author":"Thoenen","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2026.09.016_bb0145","doi-asserted-by":"crossref","first-page":"11555","DOI":"10.1200\/JCO.2021.39.15_suppl.11555","article-title":"Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma","volume":"39","author":"Copeland","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.016_bb0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1078-0432.CCR-23-2469","article-title":"SAR-096: phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS)","volume":"30","author":"Movva","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41379-021-00922-7","article-title":"TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition","volume":"35","author":"Chiang","year":"2022","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0160","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ijc.27800","article-title":"Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates","volume":"132","author":"Dickson","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111452","article-title":"Let-7 miRNA\u2019s expression profile and its potential prognostic role in uterine leiomyosarcoma","volume":"8","author":"de Almeida","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.016_bb0175","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0180","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2020.10.002","article-title":"Homologous recombination repair deficiency as a therapeutic target in sarcoma","volume":"47","author":"Oza","year":"2020","journal-title":"Semin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2026.09.016_bb0190","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1200\/JCO.2019.37.15_suppl.11048","article-title":"DNA damage response pathway alterations and clinical outcome in leiomyosarcoma","volume":"37","author":"Rosenbaum","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.016_bb0195","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1560","article-title":"The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas","volume":"13","author":"Hernando","year":"2007","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.016_bb0510","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-18-2792","article-title":"Integrated molecular analysis of undifferentiated uterine sarcomas reveals clinically relevant molecular subtypes","volume":"25","author":"Binzer-Panchal","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.016_bb0515","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41379-022-01160-1","article-title":"Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors","volume":"35","author":"Momeni Boroujeni","year":"2022","journal-title":"Mod. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:59:07Z","timestamp":1791748747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":102,"alternative-id":["S0090825826021414"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biomarkers in uterine sarcomas: a review of reviews with genomic data integration","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}